Schedule 13D ownership disclosure
Spyre Therapeutics Inc
Security class unavailable · CUSIP: 00773J202
Event date: 2023-12-07
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 10.5900%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-23-292713
- Form type
- SC 13D
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- Dec 11, 2023
- Reporting period
- Dec 07, 2023
- Description
- Schedule 13D beneficial ownership